Key Highlights

  • Liquidia shares are trading at $26.96 in Thursday's session, down 10.91% on Volume roughly nine times average.
  • A Delaware court ruled claims 1 and 14 of the '327 Patent are valid and infringed, while the other asserted claims were found invalid.
  • The parties must submit a proposed form of judgment within one week, and United Therapeutics has asked for relief that could restrict Yutrepia sales.
  • Several brokerages cut ratings or targets, including a downgrade to Neutral and a target reduction to $53 from $106.

Patent Loss Extends a Historic Selloff

Liquidia (NASDAQ:LQDA) is falling again in Thursday's session after a Delaware federal court ruled in favor of United Therapeutics (NASDAQ:UTHR) in a patent case over Yutrepia, its inhaled treprostinil powder. The shares are down about 11% at $26.96, following a drop of roughly 57% in the prior session, and volume is running about nine times average.

The Morrisville, North Carolina-based company launched Yutrepia in June 2025 for pulmonary arterial hypertension and PH-ILD, and the product has driven a sharp Revenue inflection.

What the Court Decided and What Liquidia Plans

The court ruled that claims 1 and 14 of the '327 patent, which generally cover treating PH-ILD with inhaled treprostinil including dry powder formulations, are valid and infringed. The other claims asserted against Liquidia were found invalid.

CEO Roger Jeffs said the company disagrees with the decision and is prepared to pursue all appellate options. Liquidia also intends to submit a supplement to Yutrepia's application asking the FDA to remove PH-ILD from the label.

The Remedy Remains the Biggest Unknown

The parties must submit a proposed form of judgment within one week. Liquidia said potential remedies range from removing the PH-ILD indication to broader restrictions on availability, and noted that United Therapeutics has asked for injunctive relief that would limit Yutrepia on the market.

Given potential appeals and further proceedings, the company said it cannot reasonably estimate the range of outcomes or its financial exposure.

Analysts Slash Targets as Single-Product Risk Sharpens

Several brokerages moved quickly. One cut its rating to Outperform with a $53 target, down from $106, another downgraded the stock to Neutral, and a third kept a Buy rating but lowered its target to $72. Liquidia depends on one commercial franchise, and the shares now trade near the low end of a 52-week range of $21.35 to $93.61.